- Press Releases
- Notices
Press Releases To List
-
- Sep.18.2024R & D
- Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
-
- Sep.12.2024R & D
- Ono and Bristol-Myers Squibb KK Submit Supplemental Application of Opdivo and Yervoy in Combination Treatment in Japan to Expand the Use for Unresectable Advanced or Recurrent Microsatellite Instability-High Colorectal Cancer
-
- Aug.23.2024R & D
- Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
-
- Aug.20.2024Sustainability
- Ono Selected for ESG Investment Indexes Adopted by GPIF
-
- Aug.16.2024R & D
- U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
Notices To List
-
- Jun.21.2024Corporate
- Voting Results (Extraordinary Report) of the 76th Ordinary General Shareholders’ Meeting
-
- Jun.20.2024Corporate
- Notice to Resolutions Passed at The 76th Ordinary General shareholders’ Meeting
-
- May.23.2024Corporate
- Notice to Convene the 76th Ordinary General Shareholders' Meeting
-
- May.09.2024Corporate
- Posted presentation material of Merger Agreement with Deciphera Pharmaceuticals
-
- Sep.26.2023Corporate
- Corporate Report 2023 has been released.
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.